Licensing agreement
SIRS-Lab GmbH of Jena, Germany and DxS Ltd of Manchester, UK, agreed an EU-wide in-licensing agreement to use DxS’s Scorpions genotyping technology in the SIRS-Lab sepsis prediction and monitoring test SIQNATURE.
The test is available for beta testing and will be fully available in 2009. Further details and financial terms of the agreement were not disclosed.
SIRS-Lab claims to be the first company to identify biomarkers which indicate sepsis earlier and more reliably than currently possible. It has translated these biomarkers into a rapid and easy-to-use probe based PCR test. The company says SIQNATURE will make it possible detect sepsis and then monitor its progression. Sepsis, or severe infection, is the most frequent cause of death in surgical intensive care units.
SIRS-Lab was spun out of the University Clinik of Jena in 2000, while DxS is based at the University of Manchester Incubator Company.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
Follow where the public and private R&I money is going and which collaborative opportunities you can pursue.
